Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 6.1% – Should You Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was down 6.1% during trading on Thursday . The company traded as low as $18.78 and last traded at $18.78. Approximately 135,496 shares were traded during trading, a decline of 71% from the average daily volume of 473,141 shares. The stock had previously closed at $20.00.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ARCT shares. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. HC Wainwright reiterated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They issued an “outperform” rating and a $70.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $71.40.

Arcturus Therapeutics Price Performance

The stock has a market capitalization of $510.36 million, a P/E ratio of -4.85 and a beta of 2.61. The business’s 50 day simple moving average is $21.16 and its 200-day simple moving average is $25.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. The company had revenue of $49.86 million for the quarter, compared to analysts’ expectations of $21.00 million. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. During the same period last year, the firm posted ($1.98) earnings per share. Research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current fiscal year.

Insider Transactions at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 12,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 13.80% of the company’s stock.

Institutional Trading of Arcturus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new stake in Arcturus Therapeutics in the 1st quarter valued at about $40,000. nVerses Capital LLC acquired a new position in Arcturus Therapeutics in the 3rd quarter valued at approximately $42,000. Quest Partners LLC increased its position in Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 3,579 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 2,038 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Arcturus Therapeutics in the 2nd quarter valued at $142,000. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.